Related references
Note: Only part of the references are listed.Soluble CD163 Changes Indicate Monocyte Association With Cognitive Deficits in Parkinson's Disease
Sara Konstantin Nissen et al.
MOVEMENT DISORDERS (2021)
Relationships of gut microbiota, short-chain fatty acids, inflammation, and the gut barrier in Parkinson's disease
Velma T. E. Aho et al.
MOLECULAR NEURODEGENERATION (2021)
Donanemab in Early Alzheimer's Disease
Mark A. Mintun et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data
Gennaro Pagano et al.
FRONTIERS IN NEUROLOGY (2021)
Safety and Tolerability of Active Immunotherapy Targeting α-Synuclein with PD03A in Patients with Early Parkinson's Disease: A Randomized, Placebo-Controlled, Phase 1 Study
Werner Poewe et al.
JOURNAL OF PARKINSONS DISEASE (2021)
T cell infiltration in both human multiple system atrophy and a novel mouse model of the disease
Gregory P. Williams et al.
ACTA NEUROPATHOLOGICA (2020)
Parkinson disease and the immune system - associations, mechanisms and therapeutics
Eng-King Tan et al.
NATURE REVIEWS NEUROLOGY (2020)
Immunotherapy for Parkinson's disease
Aaron D. Schwab et al.
NEUROBIOLOGY OF DISEASE (2020)
Baicalein Attenuates Neuroinflammation by Inhibiting NLRP3/Caspase-1/GSDMD Pathway in MPTP-Induced Mice Model of Parkinson's Disease
Wenjuan Rui et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2020)
Safety and immunogenicity of the α-synuclein active immunotherapeutic PDO1A in patients with Parkinson's disease: a randomised, single-blinded, phase 1 trial
Dieter Volc et al.
LANCET NEUROLOGY (2020)
T cell infiltration and upregulation of MHCII in microglia leads to accelerated neuronal loss in an α-synuclein rat model of Parkinson's disease
Meena S. Subbarayan et al.
JOURNAL OF NEUROINFLAMMATION (2020)
A Phase 1 Randomized Trial of Specific Activeα-SynucleinImmunotherapiesPD01AandPD03Ain Multiple System Atrophy
Wassilios G. Meissner et al.
MOVEMENT DISORDERS (2020)
Novel antibodies detect additional α-synuclein pathology in synucleinopathies: potential development for immunotherapy
Jacqui T. Nimmo et al.
ALZHEIMERS RESEARCH & THERAPY (2020)
Development of an aggregate-selective, human-derived α-synuclein antibody BIIB054 that ameliorates disease phenotypes in Parkinson's disease models
Andreas Weihofen et al.
NEUROBIOLOGY OF DISEASE (2019)
Randomized phase I clinical trial of anti-α-synuclein antibody BIIB054
Miroslaw Brys et al.
MOVEMENT DISORDERS (2019)
Alterations in Blood Monocyte Functions in Parkinson's Disease
Sara Konstantin Nissen et al.
MOVEMENT DISORDERS (2019)
Intrastriatal injection of preformed alpha-synuclein fibrils alters central and peripheral immune cell profiles in non-transgenic mice
Rachael H. Earls et al.
JOURNAL OF NEUROINFLAMMATION (2019)
Preclinical development of a high affinity α-synuclein antibody, MEDI1341, that can enter the brain, sequester extracellular α-synuclein and attenuate α-synuclein spreading in vivo
Darren J. Schofield et al.
NEUROBIOLOGY OF DISEASE (2019)
Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti-a-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease A Randomized Clinical Trial
Joseph Jankovic et al.
JAMA NEUROLOGY (2018)
Early microglial activation and peripheral inflammation in dementia with Lewy bodies
Ajenthan Surendranathan et al.
BRAIN (2018)
Inflammasome inhibition prevents α-synuclein pathology and dopaminergic neurodegeneration in mice
Richard Gordon et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
Cytokine profiling in the prefrontal cortex of Parkinson's Disease and Multiple System Atrophy patients
Rasmus Rydbirk et al.
NEUROBIOLOGY OF DISEASE (2017)
Modeling Parkinson's disease pathology by combination of fibril seeds and α-synuclein overexpression in the rat brain
Poonam Thakur et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
α-Synuclein fibrils recruit peripheral immune cells in the rat brain prior to neurodegeneration
Ashley S. Harms et al.
ACTA NEUROPATHOLOGICA COMMUNICATIONS (2017)
Inhibition of the JAK/STAT Pathway Protects Against α-Synuclein-Induced Neuroinflammation and Dopaminergic Neurodegeneration
Hongwei Qin et al.
JOURNAL OF NEUROSCIENCE (2016)
Fenamate NSAIDs inhibit the NLRP3 inflammasome and protect against Alzheimer's disease in rodent models
Michael J. D. Daniels et al.
NATURE COMMUNICATIONS (2016)
Lenalidomide reduces microglial activation and behavioral deficits in a transgenic model of Parkinson's disease
Elvira Valera et al.
JOURNAL OF NEUROINFLAMMATION (2015)
Active immunization against alpha-synuclein ameliorates the degenerative pathology and prevents demyelination in a model of multiple system atrophy
Markus Mandler et al.
MOLECULAR NEURODEGENERATION (2015)
Structure of the toxic core of α-synuclein from invisible crystals
Jose A. Rodriguez et al.
NATURE (2015)
Evaluation of an α synuclein sensitized dendritic cell based vaccine in a transgenic mouse model of Parkinson disease
Kenneth E. Ugen et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2015)
Anti-Human α-Synuclein N-Terminal Peptide Antibody Protects against Dopaminergic Cell Death and Ameliorates Behavioral Deficits in an AAV-α-Synuclein Rat Model of Parkinson's Disease
Md Shahaduzzaman et al.
PLOS ONE (2015)
Role of α-Synuclein in Inducing Innate and Adaptive Immunity in Parkinson Disease
Heather E. Allen Reish et al.
JOURNAL OF PARKINSONS DISEASE (2015)
Synucleins Regulate the Kinetics of Synaptic Vesicle Endocytosis
Karina J. Vargas et al.
JOURNAL OF NEUROSCIENCE (2014)
Reducing C-Terminal-Truncated Alpha-Synuclein by Immunotherapy Attenuates Neurodegeneration and Propagation in Parkinson's Disease-Like Models
Dora Games et al.
JOURNAL OF NEUROSCIENCE (2014)
Immunotherapy targeting α-synuclein protofibrils reduced pathology in (Thy-1)-h[A30P] α-synuclein mice
Veronica Lindstrom et al.
NEUROBIOLOGY OF DISEASE (2014)
A progressive dopaminergic phenotype associated with neurotoxic conversion of α-synuclein in BAC-transgenic rats
Silke Nuber et al.
BRAIN (2013)
α-Synuclein Vaccination Prevents the Accumulation of Parkinson Disease-Like Pathologic Inclusions in Striatum in Association With Regulatory T Cell Recruitment in a Rat Model
Vanesa Sanchez-Guajardo et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2013)
MHCII Is Required for α-Synuclein-Induced Activation of Microglia, CD4 T Cell Proliferation, and Dopaminergic Neurodegeneratione
Ashley S. Harms et al.
JOURNAL OF NEUROSCIENCE (2013)
Regionally-specific microglial activation in young mice over-expressing human wildtype alpha-synuclein
Melanie B. Watson et al.
EXPERIMENTAL NEUROLOGY (2012)
Intracerebral inoculation of pathological α-synuclein initiates a rapidly progressive neurodegenerative α-synucleinopathy in mice
Kelvin C. Luk et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2012)
LONG-TERM POLARIZATION OF MICROGLIA UPON α-SYNUCLEIN OVEREXPRESSION IN NONHUMAN PRIMATES
P. Barkholt et al.
NEUROSCIENCE (2012)
A Progressive Mouse Model of Parkinson's Disease: The Thy1-aSyn (Line 61) Mice
Marie-Francoise Chesselet et al.
NEUROTHERAPEUTICS (2012)
Neuroinflammation and α-Synuclein Dysfunction Potentiate Each Other, Driving Chronic Progression of Neurodegeneration in a Mouse Model of Parkinson's Disease
Hui-Ming Gao et al.
ENVIRONMENTAL HEALTH PERSPECTIVES (2011)
Anti-inflammatory drugs and risk of Parkinson disease A meta-analysis
Joshua J. Gagne et al.
NEUROLOGY (2010)
Microglia Acquire Distinct Activation Profiles Depending on the Degree of α-Synuclein Neuropathology in a rAAV Based Model of Parkinson's Disease
Vanesa Sanchez-Guajardo et al.
PLOS ONE (2010)
Dynamic Changes in Presynaptic and Axonal Transport Proteins Combined with Striatal Neuroinflammation Precede Dopaminergic Neuronal Loss in a Rat Model of AAV α-Synucleinopathy
Chee Yeun Chung et al.
JOURNAL OF NEUROSCIENCE (2009)
Alpha-Synuclein and Familial Parkinson's Disease
Nathan Pankratz et al.
MOVEMENT DISORDERS (2009)
Genome-wide association study reveals genetic risk underlying Parkinson's disease
Javier Simon-Sanchez et al.
NATURE GENETICS (2009)
Targeted Overexpression of Human α-Synuclein Triggers Microglial Activation and an Adaptive Immune Response in a Mouse Model of Parkinson Disease
Shaji Theodore et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2008)
Active and passive immunity, vaccine types, excipients and licensing
David Baxter
OCCUPATIONAL MEDICINE-OXFORD (2007)
Long-term consequences of human alpha-synuclein overexpression in the primate ventral midbrain
Andisheh Eslamboli et al.
BRAIN (2007)
The effect of truncated human alpha-synuclein (1-120) on dopaminergic cells in a transgenic mouse model of Parkinson's Disease
A. W. Michell et al.
CELL TRANSPLANTATION (2007)
Chaperone-like activities of α-synuclein:: α-Synuclein assists enzyme activities of esterases
Misun Ahn et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2006)
In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease
A Gerhard et al.
NEUROBIOLOGY OF DISEASE (2006)
Effects of α-synuclein immunization in a mouse model of Parkinson's disease
E Masliah et al.
NEURON (2005)
Aggregation promoting C-terminal truncation of α-synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations
WX Li et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Microglial activation and dopamine terminal loss in early Parkinson's disease
Y Ouchi et al.
ANNALS OF NEUROLOGY (2005)
Microglial inflammation in the parkinsonian substantia nigra: relationship to alpha-synuclein deposition
Emilie Croisier et al.
JOURNAL OF NEUROINFLAMMATION (2005)
α-synuclein locus duplication as a cause of familial Parkinson's disease
MC Chartier-Harlin et al.
LANCET (2004)
Role of α-synuclein in presynaptic dopamine recruitment
L Yavich et al.
JOURNAL OF NEUROSCIENCE (2004)
Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson's disease brains
K Imamura et al.
ACTA NEUROPATHOLOGICA (2003)
α-synuclein locus triplication causes Parkinson's disease
AB Singleton et al.
SCIENCE (2003)
Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease
HL Chen et al.
ARCHIVES OF NEUROLOGY (2003)
Nigrostriatal α-synucleinopathy induced by viral vector-mediated overexpression of human α-synuclein:: A new primate model of Parkinson's disease
D Kirik et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
α-Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease
C Lo Bianco et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Differential neuropathological alterations in transgenic mice expressing α-synuclein from the platelet-derived growth factor and Thy-1 promoters
E Rockenstein et al.
JOURNAL OF NEUROSCIENCE RESEARCH (2002)
Neuronal α-synucleinopathy with severe movement disorder in mice expressing A53T human α-synuclein
BI Giasson et al.
NEURON (2002)
Parkinson-like neurodegeneration induced by targeted overexpression of α-synuclein in the nigrostriatal system
D Kirik et al.
JOURNAL OF NEUROSCIENCE (2002)
α-Synuclein is phosphorylated in synucleinopathy lesions
H Fujiwara et al.
NATURE CELL BIOLOGY (2002)
Kinetic stabilization of the α-synuclein protofibril by a dopamine-α-synuclein adduct
KA Conway et al.
SCIENCE (2001)
Share Paper
